Cellectar Biosciences
Market cap $9.2M 10.0M shares (10-Q, Nov 6, 2026) × $0.920 close Nov 17, 2026
- FinancingLate 2026 / early 2027Financing, Late 2026 / early 2027, routine
- CLR 125 Ph1 interim4Q 2026CLR 125 Ph1 interim, 4Q 2026, major
- Iopofosine I 131 Ph3 startEarly 2027Iopofosine I 131 Ph3 start, Early 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
iopofosine I 131
CLR 131CLR 125
CLR 121125CLR 225
CLR 121225iopofosine
iopofosine I 131 · CLR 131Technology platforms
PDC
Phospholipid ether drug conjugate (PDC) platform designed to selectively deliver a diverse range of oncologic payloads to cancer cells via lipid raft-mediated uptake. Supports radioconjugates (PRCs), small molecule, peptide, and oligonucleotide payloads. Focus: broad cancer indications including hematologic malignancies and solid tumors.
Phospholipid Drug Conjugate
Proprietary PDC delivery platform leveraging phospholipid ether (PLE) technology for targeted cancer cell delivery; combinable with small-molecule chemotherapeutics, radiotherapeutics, and other therapeutic molecules; focus areas include hematologic malignancies and solid tumors
Discontinued (3)
- iopofosine — Neuroblastoma
- iopofosine — Osteosarcoma
- iopofosine — Ewing's Sarcoma
Capital (as filed)
- Cash
- $24.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$9.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $24.6M cash, runway into the second quarter of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-06-02 424B3 · Resale (selling stockholders)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-11 UPDATE: Cellectar Biosciences (CLRB) - The Warrants Went Dark 🔒 Paid
- 2026-08-14 UPDATE: Cellectar Biosciences (CLRB) - The Warrants Went Live 🔒 Paid
- 2026-05-07 Cellectar Biosciences (CLRB) - Scientific Deep Dive for Iopofosine and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Cellectar Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-07 Watch Cellectar Biosciences (CLRB) - Scientific Deep Dive for Iopofosine and Pipeline Products Strong science and removed bankruptcy risk, but complex warrant structure and execution risk warrant patience before taking a position.
- 2026-08-14 Watch UPDATE: Cellectar Biosciences (CLRB) - The Warrants Went Live Watch list maintained with downgraded urgency as 52.65M warrant shares create a structural ceiling, NDA slipped to mid-2027, and another financing raise appears likely before the key catalyst.
- 2026-11-11 Avoid UPDATE: Cellectar Biosciences (CLRB) - The Warrants Went Dark Downgraded to Avoid as milestone warrants are now effectively unreachable at $1.22, only ~two quarters of runway remain, and a deeply dilutive pre-NDA raise appears nearly unavoidable.
- Avoid call · opened Nov 11, 2026 at $1.21 · -24.0% vs XBI -7.1% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
““Most notably, we progressed our regulatory strategy for iopofosine I 131 in Waldenström macroglobulinemia, including initiation of site activation activities for our confirmatory Phase 3 trial, which is an important first step toward our accelerated approval application in the U.S., which we plan to submit in mid-2027.”
matched to CLR 125 · interim data / matched to Iopofosine I 131 · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (28)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseCellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates LEARN MORE→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateQ3 numbers confirm the burn is accelerating toward $8M/quarter while the cash clock ticks to Q2 2027 — but new IWWM data (87.5% ORR, 100% CBR, n=24 post-BTKi) and a Q4 2026 CLR 125 data signal are the most important developments hiding inside a routine quarterly filing.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseCellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Expo
- Nov 2, 2026ReleaseCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 LEARN MORE
- Oct 27, 2026ReleaseCellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 LEARN MORE
- Oct 15, 2026ReleaseCellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International WorksBD extracted 1 program update from this document → CLRB pipeline
- Sep 29, 2026ReleaseCellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International WorkshoBD extracted 1 program update from this document → CLRB pipeline
- Aug 13, 2026ReleaseCellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates LEARN MOREBD extracted 1 program update from this document → CLRB pipeline
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Aug 13, 202610-QQuarterly report
- Jul 30, 2026ReleaseCellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 LEARN MORE
- Jul 15, 2026ReleaseCellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers LEARN MOREBD extracted 1 program update from this document → CLRB pipeline
- Jul 10, 20268-KCurrent report: officer / director change, shareholder vote
- Jun 2, 2026424B3Prospectus (resale / update)
- Jun 1, 2026ReleaseCellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology AnnBD extracted 1 program update from this document → CLRB pipeline
- May 29, 2026S-1/ARegistration statement (amended)
- May 28, 2026DEFA14AProxy soliciting material
- May 28, 2026DEF 14AProxy statement
- May 19, 2026S-1Registration statement
- May 18, 20268-KCurrent report: officer / director change
- May 14, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- May 14, 202610-QQuarterly report
- May 8, 20268-KCurrent report: material agreement, unregistered sale of equity, other events
- May 6, 2026424B5Prospectus supplement (offering)
- Apr 30, 202610-K/AAnnual report (amended)
- Mar 4, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Mar 4, 202610-KAnnual report
13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 4, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 5, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 1, 2026EFFECTRegistration effective
- May 29, 2026CORRESPCORRESP
- May 22, 2026UPLOADUPLOAD
- May 18, 2026PRE 14APRE 14A
- May 11, 2026SCHEDULE 13GPassive >5% holder (13G)